Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Head-To-Head Review: Supernus Pharmaceuticals (NASDAQ:SUPN) and Chugai Pharmaceutical (OTCMKTS:CHGCY)
Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More
Why Indivior Pharmaceuticals Stock Topped the Market Today
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript
Supernus Announces Third Quarter 2026 Financial Results
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600
Is Supernus Pharmaceuticals Inc (SUPN) a Bargain After 3.3% Drop? GF Value Says Undervalued
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Rated “Hold” by Sell-Side Brokerages
Head-To-Head Contrast: Supernus Pharmaceuticals (NASDAQ:SUPN) and Shineco (NASDAQ:SISI)
Head-To-Head Contrast: Harrow (NASDAQ:HROW) & Supernus Pharmaceuticals (NASDAQ:SUPN)